BlinkRx (Blink Health) Stock
| Valuation | $2B1 |
| Valuation Date | Nov 15, 2024 |
| Implied Valuation | $1.92B |
| Last Price | $48.69 |
| 52-Week High | $48.72 |
| 52-Week Low | $30.89 |
| YTD Return | +20.55% |
| 1-Year Return | +20.55% |
| 3-Year Return | n/a |
| Total Funding | $510.25M |
| Latest Round Amount | $140M2 |
| Latest Round | Series D |
| Funding Rounds | 4 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About BlinkRx
BlinkRx is a prescription access platform that helps patients fill branded medications at a transparent price with free home delivery. Doctors send prescriptions to BlinkRx. The company then checks insurance, manufacturer discounts and prior authorizations so patients can pay online instead of finding out at the pharmacy that a drug is unaffordable or out of stock. The same company also runs Blink Quick Save and Blink Cash Express for cheaper generic cash-pay fills. BlinkRx makes money by selling this prescription-journey platform to drugmakers as a patient-access and fulfillment partner.
Invest in BlinkRx
BlinkRx is a private company, so you can't purchase it with a regular brokerage account. However, its shares are available on Clarity (formerly Hiive).
Clarity is a secondary marketplace where accredited investors can buy and sell shares of private, pre-IPO companies. Invest in the world's most exciting startups before they go public.
Invest on ClarityStock Analysis may be compensated for user sign-ups through Clarity links. Clarity is not affiliated with Stock Analysis. Securities offered by Clarity Capital Limited, member of FINRA/SIPC.
News
BlinkRx Insights: Beyond the Hub - Rethinking the Prescription Journey
BlinkRx co-founders Geoffrey and Matthew Chaiken argue in a Drug Channels guest post that point solutions and traditional hubs have fragmented the branded-prescription journey, and they pitch BlinkRx'...
BlinkRx Announces Availability of RYALTRIS® for Convenient Home Delivery Following Glenmark’s Commercial Transition
BlinkRx said Glenmark's RYALTRIS nasal spray is now available for fulfillment through its platform after Glenmark took over U.S. commercialization. Patients can get network pricing and free home deliv...
BlinkRx Welcomes Former U.S. Senator Joe Manchin, Healthcare Executive Heather Manchin, as Senior Advisors
BlinkRx appointed former Senator Joe Manchin and healthcare executive Heather Manchin, former CEO of Mylan, as senior advisors. Through Manchin Partners they will counsel BlinkRx on expanding the plat...
Following Big Pharma’s Troubling Schemes With DTC Telehealth Platforms, Durbin, Warren, Welch Sound Alarm On Launch Of TrumpRx
Senators Durbin, Warren and Welch asked HHS OIG to review TrumpRx before launch, citing Anti-Kickback concerns and a possible conflict because Donald Trump Jr. has sat on BlinkRx's board since Februar...
BlinkRx Welcomes Former Congressman Cedric Richmond as Senior Advisor
BlinkRx hired former Congressman Cedric Richmond as a senior advisor to help scale the platform. Co-founders Geoff and Matt Chaiken said he brings policy experience and stakeholder alignment as the co...
SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
U.S. Losartan market totals $245M annually with 71M prescriptions COMMACK, NY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned ph...
EXCLUSIVE: BlinkRx rips “baseless smear” linking company to TrumpRx
BlinkRx told Sens. Wyden and Reps. Pallone and Neal it first learned about TrumpRx from press reports and had no role in developing the government site. The company said Democrats' late-October inquir...
In wake of Trump's request for direct drug sales, BlinkRx debuts off-the-shelf DTC platform for pharmas
Fierce Pharma reports BlinkRx launched Operation Access Now days after President Trump asked drugmakers to offer direct-to-consumer distribution, claiming manufacturers can stand up a DTP channel in 2...
BlinkRx Welcomes Donald Trump Jr. to Board of Directors
BlinkRx appointed 1789 Capital partner Donald Trump Jr. to its board after 1789 led the company's $140 million Series D. Governor Kelly Ayotte stepped down from the board to become New Hampshire's gov...
'Anti-Woke' 1789 Capital Bets on Drug Startup BlinkRx
Bloomberg reported 1789 Capital led a $140 million round valuing BlinkRx at roughly $2 billion, with Fidelity, 8VC, Cercano Management and Sweetwater Private Equity also investing. The digital pharmac...
Assertio Holdings, Inc. Partners with BlinkRx to Support Healthcare Providers and Patients Utilizing Otrexup® (methotrexate) with a Unique Patient Access Solution
Collaboration Eases Patient Access to Therapy Collaboration Eases Patient Access to Therapy
Blink Health says has raised a $90 million series B led by 8VC
Blink Health said it raised a $90 million Series B led by 8VC, bringing total financing to $165 million. The 2017 round is the company's last publicly announced raise before the later Series C and 202...